



## Vaccination for Monkeypox Infection in Humans

Guest Editor:

### Dr. Kay Choong See

Division of Respiratory and  
Critical Care Medicine,  
Department of Medicine,  
National University Hospital,  
Singapore 119228, Singapore

Deadline for manuscript  
submissions:

**closed (31 December 2023)**

### Message from the Guest Editor

Dear Colleagues,

Monkeypox virus infection in humans is an evolving public health concern, with thousands of cases reported in >50 countries. Given the significant and rapid global spread of monkeypox, the World Health Organization declared monkeypox a global health emergency on 23 July 2022. Vaccination is an important strategy for mitigating the monkeypox outbreak, but contemporary data on its efficacy, utility and adverse effects are needed.

Therefore, we are pleased to invite you to contribute original research and reviews that will help to develop existing knowledge with respect to vaccination for monkeypox virus infection in humans. All relevant studies will be considered, including those related to basic science, translational research, clinical practice, epidemiology and population health.

I look forward to receiving your contributions.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ralph A. Tripp

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)